Drug intelligence / Profile preview

becotatug + osimertinib

Development stage: Unknown
Lead developer: Shanghai Jinmante Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Combination therapy of becotatug and osimertinib for the treatment of EGFR-mutated non-small cell lung cancer. Becotatug is a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), while osimertinib is a third-generation EGFR tyrosine kinase inhibitor. This combination is being investigated particularly for patients with EGFR exon 20 insertion mutations in NSCLC.

Brand names: Tagrisso + becotatug

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on becotatug + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on becotatug + osimertinib.

Explore the full profile